GLS inhibitor telaglenastat has shown promising results in preclinical studies and is currently being investigated in a clinical trial for patients with IDH mutant gliomas in combination with radiation therapy and temozolomide (NCT 2018). The gene discussed is IDH1; the disease is glioma.